
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$2.06
+US$0.05 · +2.49%
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
前收盤價
US$2.06
+US$0.05 · +2.49%
盤中時間採用ET。市場資料可能有所延遲。
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
日內區間
目前US$2.06
52週區間
目前US$2.06
盤中時間採用ET。市場資料可能有所延遲。
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
日內區間
目前US$2.06
52週區間
目前US$2.06
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 302.2萬 USD | 176.1萬 USD | 130.2萬 USD | 6996.3萬 USD | 257.3萬 USD |
| 銷貨成本 | — | — | — | 139.7萬 USD | 140.2萬 USD |
| 毛利 | 302.2萬 USD | 176.1萬 USD | 130.2萬 USD | 6856.6萬 USD | 117.1萬 USD |
| 銷售、一般及管理費用 | 685.2萬 USD | 609.6萬 USD | 890.3萬 USD | 5671萬 USD | 8074.8萬 USD |
| 營業費用 | 723.6萬 USD | 660.5萬 USD | 982.5萬 USD | 5790.3萬 USD | 8074.8萬 USD |
| 利息收入 | 15萬 USD | — | 30萬 USD | — | — |
| 利息支出 | 8000 USD | — | 20萬 USD | — | 3291.7萬 USD |
| 折舊和攤銷 | 119.3萬 USD | 50.9萬 USD | 92.2萬 USD | 120萬 USD | 73.6萬 USD |
| 營業利益 | −421.4萬 USD | −484.4萬 USD | −852.3萬 USD | 1066.3萬 USD | −7957.7萬 USD |
| 淨利 | −56.9萬 USD | −218.1萬 USD | −1027.8萬 USD | 1.12億 USD | −1.72億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2022年5月9日 | 1:50 | — | — |
股票分割 | 2011年10月3日 | 1:100 | — | — |
股票分割 | 2009年7月27日 | 3:1 | — | — |
已生效 2022年5月9日
1:50
已生效 2011年10月3日
1:100
已生效 2009年7月27日
3:1
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。